We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 11, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. (UNH - Free Report) , Pfizer Inc. (PFE - Free Report) , BlackRock, Inc. (BLK - Free Report) , The Hershey Co. (HSY - Free Report) and Edison International (EIX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for UnitedHealth, Pfizer and BlackRock
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Inc., Pfizer Inc. and BlackRock, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of UnitedHealth have underperformed the Zacks Medical - HMOs industry over the past year (-10.4% vs. -5.6%). The company's membership in its global business continues to be a concern. High operating costs due to rising medical expenses are hurting margins. As such, the stock warrants a cautious stance.
Nevertheless, UnitedHealth Group's top line remains poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. The company's solid health services segment provides diversification benefits.
The Government business remains well-poised for growth in the future. A sturdy balance sheet enables business investments and prudent deployment of capital via share repurchases and dividend payments.
Pfizer's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-32.6% vs. +22.3%). The company's top line declined in 2023 due to a steep drop in revenues from its COVID-19 products, Comirnaty vaccine and Paxlovid oral pill, on lower demand. Concerns remain about its long-term growth drivers beyond its COVID products due to competitive pressure.
Nonetheless, Pfizer boasts a diversified portfolio of innovative drugs and vaccines. Pfizer expects better non-COVID operational revenue growth in the future quarters, driven by its in-line products like the Vyndaqel family, new launches like Abrysvo, Velsipity, Penbraya, Zavzpret and newly acquired products, including those acquired from Seagen. Estimates have declined slightly ahead of Q1 earnings. Pfizer has a positive record of earnings surprises in recent quarters.
Shares of BlackRock have gained +26.7% over the past six months against the Zacks Financial - Investment Management industry's gain of +30.1%. The company's efforts to restructure the equity business and solid assets under management (AUM) balance will keep supporting the top line.
BlackRock's planned buyouts of 75% stake in SpiderRock and Global Infrastructure Partners will enhance revenue mix. Elevated costs (mainly owing to higher general and administrative costs) are expected to hurt the bottom line.
Its dependence on overseas revenues exposes it to geopolitical tensions, different regulatory/economic environments and exchange rate fluctuation. Nevertheless, the company's robust capital distributions reflect a solid liquidity position.
Other noteworthy reports we are featuring today include The Hershey Co. and Edison International.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights UnitedHealth, Pfizer, BlackRock, The Hershey and Edison International
For Immediate Release
Chicago, IL – April 11, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. (UNH - Free Report) , Pfizer Inc. (PFE - Free Report) , BlackRock, Inc. (BLK - Free Report) , The Hershey Co. (HSY - Free Report) and Edison International (EIX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for UnitedHealth, Pfizer and BlackRock
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including UnitedHealth Group Inc., Pfizer Inc. and BlackRock, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of UnitedHealth have underperformed the Zacks Medical - HMOs industry over the past year (-10.4% vs. -5.6%). The company's membership in its global business continues to be a concern. High operating costs due to rising medical expenses are hurting margins. As such, the stock warrants a cautious stance.
Nevertheless, UnitedHealth Group's top line remains poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. The company's solid health services segment provides diversification benefits.
The Government business remains well-poised for growth in the future. A sturdy balance sheet enables business investments and prudent deployment of capital via share repurchases and dividend payments.
(You can read the full research report on UnitedHealth here >>>)
Pfizer's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-32.6% vs. +22.3%). The company's top line declined in 2023 due to a steep drop in revenues from its COVID-19 products, Comirnaty vaccine and Paxlovid oral pill, on lower demand. Concerns remain about its long-term growth drivers beyond its COVID products due to competitive pressure.
Nonetheless, Pfizer boasts a diversified portfolio of innovative drugs and vaccines. Pfizer expects better non-COVID operational revenue growth in the future quarters, driven by its in-line products like the Vyndaqel family, new launches like Abrysvo, Velsipity, Penbraya, Zavzpret and newly acquired products, including those acquired from Seagen. Estimates have declined slightly ahead of Q1 earnings. Pfizer has a positive record of earnings surprises in recent quarters.
(You can read the full research report on Pfizer here >>>)
Shares of BlackRock have gained +26.7% over the past six months against the Zacks Financial - Investment Management industry's gain of +30.1%. The company's efforts to restructure the equity business and solid assets under management (AUM) balance will keep supporting the top line.
BlackRock's planned buyouts of 75% stake in SpiderRock and Global Infrastructure Partners will enhance revenue mix. Elevated costs (mainly owing to higher general and administrative costs) are expected to hurt the bottom line.
Its dependence on overseas revenues exposes it to geopolitical tensions, different regulatory/economic environments and exchange rate fluctuation. Nevertheless, the company's robust capital distributions reflect a solid liquidity position.
(You can read the full research report on BlackRock here >>>)
Other noteworthy reports we are featuring today include The Hershey Co. and Edison International.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.